A Retrospective Study to Evaluate the Effectiveness of onabotulinumtoxinA in Preventing Headaches in Patients With Chronic Migraines

Sponsor
Allergan (Industry)
Overall Status
Withdrawn
CT.gov ID
NCT01749423
Collaborator
(none)
0
13

Study Details

Study Description

Brief Summary

This study will evaluate the effectiveness of OnabotulinumtoxinA to prevent headaches in patients with Chronic Migraine.

Condition or Disease Intervention/Treatment Phase
  • Biological: OnabotulinumtoxinA

Study Design

Study Type:
Observational
Actual Enrollment :
0 participants
Observational Model:
Case-Only
Time Perspective:
Retrospective
Study Start Date :
Nov 1, 2012
Anticipated Primary Completion Date :
Dec 1, 2013
Anticipated Study Completion Date :
Dec 1, 2013

Arms and Interventions

Arm Intervention/Treatment
All participants

Previous treatment with onabotulinumtoxinA for Chronic Migraine based on retrospective review of medical records.

Biological: OnabotulinumtoxinA
Previous treatment with onabotulinumtoxinA for Chronic Migraine.
Other Names:
  • botulinum toxin Type A
  • BOTOX®
  • Outcome Measures

    Primary Outcome Measures

    1. Number of Headache Days [Up to 56 Weeks]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 65 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • History of chronic migraines

    • 15 or more headache days over a 30 day period

    • A minimum of 2 consecutive treatment cycles of 100 units onabotulinumtoxinA and a minimum of 2 consecutive treatment cycles with the onabotulinumtoxinA dosing between 155 and 195 units

    Exclusion Criteria:
    • Any treatment cycle dose of onabotulinumtoxinA greater than 200 units

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Allergan

    Investigators

    • Study Director: Medical Director, Allergan

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Allergan
    ClinicalTrials.gov Identifier:
    NCT01749423
    Other Study ID Numbers:
    • GMA-BTX-CM-12-518
    First Posted:
    Dec 13, 2012
    Last Update Posted:
    Feb 3, 2014
    Last Verified:
    Jan 1, 2014

    Study Results

    No Results Posted as of Feb 3, 2014